We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Early phase 2 trial of TAS‐205 in patients with Duchenne muscular dystrophy.
- Authors
Komaki, Hirofumi; Maegaki, Yoshihiro; Matsumura, Tsuyoshi; Shiraishi, Kazuhiro; Awano, Hiroyuki; Nakamura, Akinori; Kinoshita, Satoru; Ogata, Katsuhisa; Ishigaki, Keiko; Saitoh, Shinji; Funato, Michinori; Kuru, Satoshi; Nakayama, Takahiro; Iwata, Yasuyuki; Yajima, Hiroyuki; Takeda, Shin'ichi
- Abstract
Objective: Duchenne muscular dystrophy (DMD) is a progressive muscular disease characterized by chronic cycles of inflammatory and necrotic processes. Prostaglandin D2 (PGD2) is produced by hematopoietic PGD synthase (HPGDS), which is pathologically implicated in muscle necrosis. This randomized, double‐blind, placebo‐controlled early phase 2 study (NCT02752048) aimed to assess the efficacy and safety of the novel selective HPGDS inhibitor, TAS‐205, with exploratory measures in male DMD patients aged ≥5 years. Methods: Patients were randomized 1:1:1 to receive low‐dose TAS‐205 (6.67–13.33 mg/kg/dose), high‐dose TAS‐205 (13.33–26.67 mg/kg/dose), or placebo. The primary endpoint was the change from baseline in a 6‐minute walk distance (6MWD) at Week 24. Results: Thirty‐six patients were enrolled, of whom 35 patients were analysed for safety. The mean (standard error) changes from baseline to Week 24 in 6MWD were −17.0 (17.6) m in the placebo group (n = 10), −3.5 (20.3) m in the TAS‐205 low‐dose group (n = 11), and −7.5 (11.2) m in the TAS‐205 high‐dose group (n = 11). The mean (95% confidence interval) difference from the placebo group was 13.5 (−43.3 to 70.2) m in the TAS‐205 low‐dose group and 9.5 (−33.3 to 52.4) m in the TAS‐205 high‐dose group. No obvious differences were observed in the incidences of adverse events between treatment groups. No adverse drug reactions specific to TAS‐205 treatment were observed. Interpretation: The HPGDS inhibitor TAS‐205 showed a favorable safety profile in DMD patients. Further research is required to examine the effectiveness of TAS‐205 in a larger trial.
- Subjects
DUCHENNE muscular dystrophy; DRUG side effects; CHRONIC diseases
- Publication
Annals of Clinical & Translational Neurology, 2020, Vol 7, Issue 2, p181
- ISSN
2328-9503
- Publication type
Article
- DOI
10.1002/acn3.50978